These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 24101737)

  • 1. Comparative drug pair screening across multiple glioblastoma cell lines reveals novel drug-drug interactions.
    Schmidt L; Kling T; Monsefi N; Olsson M; Hansson C; Baskaran S; Lundgren B; Martens U; Häggblad M; Westermark B; Forsberg Nilsson K; Uhrbom L; Karlsson-Lindahl L; Gerlee P; Nelander S
    Neuro Oncol; 2013 Nov; 15(11):1469-78. PubMed ID: 24101737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case-specific potentiation of glioblastoma drugs by pterostilbene.
    Schmidt L; Baskaran S; Johansson P; Padhan N; Matuszewski D; Green LC; Elfineh L; Wee S; Häggblad M; Martens U; Westermark B; Forsberg-Nilsson K; Uhrbom L; Claesson-Welsh L; Andäng M; Sintorn IM; Lundgren B; Lönnstedt I; Krona C; Nelander S
    Oncotarget; 2016 Nov; 7(45):73200-73215. PubMed ID: 27689322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.
    Joshi AD; Loilome W; Siu IM; Tyler B; Gallia GL; Riggins GJ
    PLoS One; 2012; 7(10):e44372. PubMed ID: 23056179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs.
    Jiang P; Mukthavaram R; Chao Y; Bharati IS; Fogal V; Pastorino S; Cong X; Nomura N; Gallagher M; Abbasi T; Vali S; Pingle SC; Makale M; Kesari S
    J Transl Med; 2014 Jan; 12():13. PubMed ID: 24433351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ROS1 amplification mediates resistance to gefitinib in glioblastoma cells.
    Aljohani H; Koncar RF; Zarzour A; Park BS; Lee SH; Bahassi el M
    Oncotarget; 2015 Aug; 6(24):20388-95. PubMed ID: 25978031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status.
    Cemeus C; Zhao TT; Barrett GM; Lorimer IA; Dimitroulakos J
    J Neurooncol; 2008 Oct; 90(1):9-17. PubMed ID: 18566746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
    Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
    J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy.
    Skaga E; Skaga IØ; Grieg Z; Sandberg CJ; Langmoen IA; Vik-Mo EO
    J Cancer Res Clin Oncol; 2019 Jun; 145(6):1495-1507. PubMed ID: 31028540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines.
    Sooman L; Ekman S; Andersson C; Kultima HG; Isaksson A; Johansson F; Bergqvist M; Blomquist E; Lennartsson J; Gullbo J
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):329-40. PubMed ID: 23736154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exhaustive in vitro evaluation of the 9-drug cocktail CUSP9 for treatment of glioblastoma.
    Chantzi E; Hammerling U; Gustafsson MG
    Comput Biol Med; 2024 Aug; 178():108748. PubMed ID: 38925084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CXCR4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme.
    Daniele S; La Pietra V; Piccarducci R; Pietrobono D; Cavallini C; D'Amore VM; Cerofolini L; Giuntini S; Russomanno P; Puxeddu M; Nalli M; Pedrini M; Fragai M; Luchinat C; Novellino E; Taliani S; La Regina G; Silvestri R; Martini C; Marinelli L
    Eur J Pharmacol; 2021 Apr; 897():173936. PubMed ID: 33581134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells.
    Song WS; Yang YP; Huang CS; Lu KH; Liu WH; Wu WW; Lee YY; Lo WL; Lee SD; Chen YW; Huang PI; Chen MT
    J Chin Med Assoc; 2016 Oct; 79(10):538-45. PubMed ID: 27530866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with 5-azacitidine delay growth of glioblastoma xenografts: a potential new treatment approach for glioblastomas.
    Kratzsch T; Kuhn SA; Joedicke A; Hanisch UK; Vajkoczy P; Hoffmann J; Fichtner I
    J Cancer Res Clin Oncol; 2018 May; 144(5):809-819. PubMed ID: 29427211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.
    Berenguer-Daizé C; Astorgues-Xerri L; Odore E; Cayol M; Cvitkovic E; Noel K; Bekradda M; MacKenzie S; Rezai K; Lokiec F; Riveiro ME; Ouafik L
    Int J Cancer; 2016 Nov; 139(9):2047-55. PubMed ID: 27388964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
    Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
    Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arginine deprivation by arginine deiminase of Streptococcus pyogenes controls primary glioblastoma growth in vitro and in vivo.
    Fiedler T; Strauss M; Hering S; Redanz U; William D; Rosche Y; Classen CF; Kreikemeyer B; Linnebacher M; Maletzki C
    Cancer Biol Ther; 2015; 16(7):1047-55. PubMed ID: 25774632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gefitinib selectively inhibits tumor cell migration in EGFR-amplified human glioblastoma.
    Parker JJ; Dionne KR; Massarwa R; Klaassen M; Foreman NK; Niswander L; Canoll P; Kleinschmidt-Demasters BK; Waziri A
    Neuro Oncol; 2013 Aug; 15(8):1048-57. PubMed ID: 23749785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tetra-O-methyl nordihydroguaiaretic acid, an inhibitor of Sp1-mediated survivin transcription, induces apoptosis and acts synergistically with chemo-radiotherapy in glioblastoma cells.
    Castro-Gamero AM; Borges KS; Moreno DA; Suazo VK; Fujinami MM; de Paula Gomes Queiroz R; de Oliveira HF; Carlotti CG; Scrideli CA; Tone LG
    Invest New Drugs; 2013 Aug; 31(4):858-70. PubMed ID: 23299390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. β-Elemene enhances the efficacy of gefitinib on glioblastoma multiforme cells through the inhibition of the EGFR signaling pathway.
    Mu L; Wang T; Chen Y; Tang X; Yuan Y; Zhao Y
    Int J Oncol; 2016 Oct; 49(4):1427-36. PubMed ID: 27498706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes.
    Guo L; Fan L; Pang Z; Ren J; Ren Y; Li J; Chen J; Wen Z; Jiang X
    J Control Release; 2011 Aug; 154(1):93-102. PubMed ID: 21609741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.